Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer

References

• Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2: 569–79. [PubMed Abstract].
   Google Scholar
• Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G. The biogenesis and functions of exosomes. Traffic. 2002; 3: 321–30. [PubMed Abstract].
   Google Scholar
• Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009; 19: 43–51. [PubMed Abstract].
   Google Scholar
• Di Vizio D, Kim J, Hager MH, Morello M, Yang W, Lafargue CJ et al. Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 2009; 69: 5601–9. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18: 883–91. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008; 10: 619–24. [PubMed Abstract].
   Google Scholar
• Shao H, Chung J, Balaj L, Charest A, Bigner DD, Carter BS et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med. 2012; 18: 1835–40. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10: 1470–6. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• McDermott U, Settleman J. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol. 2009; 27: 5650–9. [PubMed Abstract].
   Google Scholar
• Bernards R. It's diagnostics, stupid. Cell. 2010; 141: 13–17. [PubMed Abstract].
   Google Scholar
• Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012; 366: 207–15. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol. 2011; 29: 166–73. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007; 318: 287–90. [PubMed Abstract].
   Google Scholar
• Pegtel DM, Cosmopoulos K, Thorley-Lawson DA, van Eijndhoven MA, Hopmans ES, Lindenberg JL et al. Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA. 2010; 107: 6328–33. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem. 1996; 68: 850–8. [PubMed Abstract].
   Google Scholar
• Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008; 26: 1367–72. [PubMed Abstract].
   Google Scholar
• Liu H, Sadygov RG, Yates JR 3rd.. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem. 2004; 76: 4193–201. [PubMed Abstract].
   Google Scholar
• Pham TV, Piersma SR, Warmoes M, Jimenez CR. On the beta-binomial model for analysis of spectral count data in label-free tandem mass spectrometry-based proteomics. Bioinformatics. 2010; 26: 363–9. [PubMed Abstract].
   Google Scholar
• Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002; 298: 1912–34. [PubMed Abstract].
   Google Scholar
• Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010; 141: 1117–34. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Chen JY, Lin JR, Cimprich KA, Meyer T. A two-dimensional ERK-AKT signaling code for an NGF-triggered cell-fate decision. Mol Cell. 2012; 45(2): 196–209. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129–39. [PubMed Abstract].
   Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507–16. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012; 486: 537–40. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Nilsson RJ, Balaj L, Hulleman E, van Rijn S, Pegtel DM, Walraven M. Blood platelets contain tumor-derived RNA biomarkers. Blood. 2011; 118(13): 3680–3. [PubMed Abstract].
   Google Scholar
• Cox J, Mann M. Is proteomics the new genomics?. Cell. 2007; 130: 395–8. [PubMed Abstract].
   Google Scholar
• Taguchi F, Solomon B, Gregorc V, Roder H, Gray R, Kasahara K et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007; 99: 838–46. [PubMed Abstract].
   Google Scholar
• Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schoffski P et al. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res. 2009; 15: 5869–77. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012; 13: 827–37. [PubMed Abstract].
   Google Scholar
• Taguchi A, Politi K, Pitteri SJ, Lockwood WW, Faca VM, Kelly-Spratt K et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell. 2011; 20: 289–99. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol. 2008; 26: 897–906. [PubMed Abstract].
   Google Scholar
• Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009; 15: 5902–9. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol. 2006; 24: 4309–16. [PubMed Abstract].
   Google Scholar
• Piersma SR, Labots M, Verheul HM, Jimenez CR. Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods. Anal Bioanal Chem. 2010; 397: 3163–71. [PubMed Abstract].
   Google Scholar
• Yuana Y, Bertina RM, Osanto S. Pre-analytical and analytical issues in the analysis of blood microparticles. Thromb Haemost. 2011; 105: 396–408. [PubMed Abstract].
   Google Scholar
• Wilmott JS, Menzies AM, Haydu LE, Capper D, Preusser M, Zhang YE et al. BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. Br J Cancer. 2013; 108: 924–31. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar